Sanofi (0A2V)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 40.98 |
|---|---|
| 52-week range | 39.19 – 47.81 |
| Return, 1 month / 3 months | −3.7% / −5.3% |
| Return, 1 year / 3 years | −12.5% / +11.2% |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 22.7% |
| Worst drawdown (1 year) | -17.5% |
| Average daily value traded | 1.54M USD |
| Dividend yield | 10.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Sanofi is a pharmaceutical company based in France that researches, develops and makes medicines and vaccines. It supplies prescription treatments for conditions such as diabetes, cardiovascular disease, rare diseases and cancer, and it produces vaccines for influenza and other infections. It also sells consumer healthcare products, including over-the-counter remedies, to pharmacies and patients. Its customers are mainly hospitals, doctors, pharmacists and health systems in many countries around the world.
On this site Sanofi appears as a stock on the London Exchange (UK), code 0A2V, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Sanofi (0A2V) trades on the London Exchange in UK. It last closed at USD 40.98 on 21 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 1,685 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 12.5% and over the last three months it fell 5.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 45 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -4.3% | ||
| From 52-week high | -13.9% | ||
| Momentum | 36 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -5.3% | ||
| 6-month return | -1.9% | ||
| 12-month return, skipping the last month | -9.1% | ||
| Stability (higher is calmer) | 80 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.5% | ||
| Liquidity | 57 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.54M USD | ||
| Zero-volume days | 1.7% | ||
| Income | 69 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 10.2% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +2.8% |
|---|---|
| 1 month | −3.7% |
| 3 months | −5.3% |
| 6 months | −1.9% |
| 1 year | −12.5% |
| 3 years | +11.2% |
| 5 years | +4.2% |
Signals
| 50-day / 200-day average | 42.55 / 42.81 |
|---|---|
| Golden / death cross (60 days) | Death, 6 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.79 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | EUR 2.4190 |
| 4 May 2026 | EUR 1.7669 |
| 9 May 2025 | EUR 2.1953 |
| 9 May 2024 | EUR 2.0369 |
| 30 May 2023 | EUR 1.9001 |
| 25 May 2023 | EUR 1.5596 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.